Regorafenib from Bayer Submitted to Health Authorities Seeking Approval in Second-Line Treatment of Liver Cancer (for specialized target groups only)

Regulatory submissions in the U.S., Japan and Europe were completed based on data from the Phase III RESORCE study, in which regorafenib demonstrated statistically significant improvement in overall survival / Currently there are no approved therapies for the treatment of unresectable hepatocellular carcinoma (HCC) in the second-line setting
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news